利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.023 秒)

    Immunotherapeutic compositions and methods
    1.
    发明申请
    Immunotherapeutic compositions and methods 审中-公开
    免疫治疗组合物和方法

    公开(公告)号：US20070269457A1

    公开(公告)日：2007-11-22

    申请号：US11435032

    申请日：2006-05-16

    申请人： Kayvan Niazi ,  Shahrooz Rabizadeh ,  Dale Bredesen

    发明人： Kayvan Niazi ,  Shahrooz Rabizadeh ,  Dale Bredesen

    IPC分类号： A61K39/145 ,  C12N15/86 ,  C12N7/01 ,  C07K14/11

    CPC分类号： A61K39/145 ,  A61K39/12 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/585 ,  A61K2039/6031 ,  C07K2319/00 ,  C12N2760/16134

    摘要： A vaccine is described which provides protection against a broad spectrum of viral strains, including but not limited to influenza A strains such as H1N1, H3N2, and H5N1. Embodiments of the present invention offer a number of advantages over conventional vaccine, in that they are cheaper to synthesize, more stable, easily scalable, and amenable to further genetic manipulation. Most importantly, certain embodiments of the present invention contemplate features, including but not limited to endosomal targeting, which result in a more robust immune response.

    摘要翻译： 描述了提供针对广谱病毒株的保护的疫苗，包括但不限于甲型流感病毒株如H1N1，H3N2和H5N1。 本发明的实施方案相对于常规疫苗提供了许多优点，因为它们合成更便宜，更稳定，易于扩展，并且适于进一步的遗传操作。 最重要的是，本发明的某些实施方案考虑了特征，包括但不限于内体靶向，其导致更强的免疫应答。

    Reagents and methods for cancer treatment and prevention
    2.
    发明申请
    Reagents and methods for cancer treatment and prevention 有权
    癌症治疗和预防的试剂和方法

    公开(公告)号：US20070224207A1

    公开(公告)日：2007-09-27

    申请号：US11389695

    申请日：2006-03-27

    申请人： Kayvan Niazi ,  Shahrooz Rabizadeh ,  Dale Bredesen

    发明人： Kayvan Niazi ,  Shahrooz Rabizadeh ,  Dale Bredesen

    IPC分类号： A61K39/00 ,  A61K31/365

    CPC分类号： G01N33/5023 ,  A61K31/365 ,  A61K39/0011 ,  A61K2039/5154 ,  G01N2333/90241 ,  G01N2500/10

    摘要： The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.

    摘要翻译： 本发明一般涉及癌症的预防和/或治疗，更具体地涉及治疗包括实体瘤及其转移瘤在内的肿瘤，无辐射或标准化学治疗剂。 在一个实施方案中，本发明涉及一种方法，其包括：a）向受试者提供肿瘤细胞，b）从所述受试者中除去至少一部分所述肿瘤细胞以产生去除的细胞，c）将至少一部分所述去除的细胞 离体使用刺激剂，包括毒胡萝卜素和/或毒胡萝卜素相关化合物，以产生经治疗的肿瘤细胞; 和d）将所述经处理的肿瘤细胞（或其片段）体内引入相同受试者以产生抗癌治疗效果。

    Artificially designed pore-forming proteins with anti-tumor effects
    4.
    发明申请
    Artificially designed pore-forming proteins with anti-tumor effects 审中-公开
    人造设计的具有抗肿瘤作用的成孔蛋白

    公开(公告)号：US20050256040A1

    公开(公告)日：2005-11-17

    申请号：US10846479

    申请日：2004-05-14

    申请人： Dale Bredesen ,  H. Michael Ellerby

    发明人： Dale Bredesen ,  H. Michael Ellerby

    IPC分类号： A61K38/17

    CPC分类号： A61K38/17

    摘要： Protein engineering is an emerging area that has expanded the understanding in the art of protein folding and laid the groundwork for the creation of unprecedented structures with unique functions. The first native-like pore-forming protein, small globular protein (SGP), has previously been designed. It has now been discovered that this artificially engineered protein, and analogs and homologs thereof, have membrane-disrupting properties and anti-tumor activity in several cancer animal models. A mechanism for the selectivity of SGP toward cell membranes in tumors is proposed and validated herein, thereby confirming the proposed mechanism of action. Thus, SGP is established herein as the prototype for a new class of artificial proteins designed for therapeutic applications.

    摘要翻译： 蛋白质工程是一个新兴领域，扩大了蛋白质折叠技术的理解，为创造具有独特功能的前所未有的结构奠定了基础。 先前设计了第一种天然样成孔蛋白，小球状蛋白（SGB）。 现在已经发现，这种人工设计的蛋白质及其类似物和同系物在几种癌症动物模型中具有膜破坏性质和抗肿瘤活性。 本文提出并验证了SGP对肿瘤细胞膜选择性的机制，从而证实了所提出的作用机制。 因此，本文建立SGP作为为治疗应用设计的新类型人造蛋白的原型。

    Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires
    6.
    发明申请
    Targeted-assisted iterative screening (tais):a novel screening format for large molecular repertoires 审中-公开
    靶向辅助迭代筛查（Tais）：大分子谱系的新型筛选方法

    公开(公告)号：US20060099713A1

    公开(公告)日：2006-05-11

    申请号：US10515210

    申请日：2002-10-01

    申请人： Alexei Kourakine ,  Dale Bredesen

    发明人： Alexei Kourakine ,  Dale Bredesen

    IPC分类号： G01N33/00

    CPC分类号： C40B40/02 ,  C12N15/1037 ,  G01N33/6845

    摘要： This invention provides a new in vitro screening method for the detection of protein-protein and other interactions. The method has been developed and applied to a commercial cDNA library to search for novel protein-protein interactions. PDZ, WW and SH3 domains from PSD95, Nedd4, Src, Abl and Crk proteins were used as test targets. 12 novel putative and 2 previously reported interactions were identified for 6 protein interaction modules in test screens. The novel screening format, dubbed TAIS (target-assisted iterative screening), provides an alternative platform to existing technologies for a pair-wise characterization of protein-protein, and other, interactions.

    摘要翻译： 本发明提供了用于检测蛋白质和其他相互作用的新的体外筛选方法。 该方法已被开发并应用于商业cDNA文库以寻找新的蛋白质 - 蛋白质相互作用。 使用PSD95，Nedd4，Src，Abl和Crk蛋白的PDZ，WW和SH3结构域作为测试对象。 在测试屏幕中，为6个蛋白质相互作用模块确定了12个新的推定和2个先前报道的相互作用。 被称为TAIS（目标辅助迭代筛选）的新型筛选方法为现有技术提供了一个替代平台，用于蛋白质蛋白质和其他相互作用的成对表征。

    MODULATORS OF PARAPTOSIS AND RELATED METHODS
    7.
    发明申请
    MODULATORS OF PARAPTOSIS AND RELATED METHODS 有权
    PARAPTOSIS的调制器和相关方法

    公开(公告)号：US20050244894A1

    公开(公告)日：2005-11-03

    申请号：US10202503

    申请日：2002-07-23

    申请人： Sabina Sperandio ,  Susana Castro-Obregon ,  Dale Bredesen

    发明人： Sabina Sperandio ,  Susana Castro-Obregon ,  Dale Bredesen

    IPC分类号： A61K31/00 ,  A61K31/198 ,  A61K31/40 ,  A61K31/421 ,  A61K31/739 ,  A61K38/04 ,  A61K38/17 ,  A61K38/19 ,  A61K38/48 ,  A61K45/06 ,  G01N33/50 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/567

    CPC分类号： G01N33/5058 ,  A61K31/00 ,  A61K31/198 ,  A61K31/40 ,  A61K31/421 ,  A61K31/739 ,  A61K38/046 ,  A61K38/1709 ,  A61K38/191 ,  A61K38/4873 ,  A61K45/06 ,  G01N33/5008 ,  G01N33/5041 ,  G01N2510/00

    摘要： The invention is directed to a method of identifying a compound that modulates SP-induced paraptosis by (a) contacting a population of cells with an effective amount of substance P to induce SP-induced paraptosis; (b) contacting a first sub-population of the cells with a test-compound, and a second sub-population of the cells with a control-compound; and (c) comparing the amount of cell death between the first and second sub-populations of cells, where a difference in the amount of cell death between the first and second sub-populations of cells indicates that the test-compound is a compound that modulates SP-induced paraptosis. The invention is also directed to a method of treating a condition associated with excessive cell accumulation by administering to a subject in need of such treatment an effective amount of a compound identified from the method described above where the effective amount of the compound increases SP-induced paraptosis. The invention is further directed to a method of treating a condition associated with excessive cell death by administering to a subject in need of such treatment an effective amount of a compound identified from the method described above where the effective amount of the compound decreases SP-induced paraptosis.

    摘要翻译： 本发明涉及一种通过（a）使有效量的物质P与细胞群接触以诱导SP诱导的parapptosis来鉴定调节SP诱导的parapptosis的化合物的方法; （b）使细胞的第一亚群与测试化合物和细胞的第二亚群与对照化合物接触; 和（c）比较细胞的第一和第二亚群之间的细胞死亡量，其中细胞的第一和第二亚群之间的细胞死亡量的差异表明测试化合物是化合物， 调节SP诱导的parapptosis。 本发明还涉及通过向需要这种治疗的受试者施用有效量的由上述方法鉴定的化合物，其中化合物的有效量增加SP诱导的方法，治疗与过量细胞积累相关的病症的方法 parapptosis。 本发明还涉及通过向需要这种治疗的受试者施用有效量的由上述方法鉴定的化合物，其中化合物的有效量降低SP诱导的方法，治疗与过量细胞死亡相关的病症的方法 parapptosis。